Skip to content
HowShorted

Rallybio Corp short interest in 2023

In 2023, Rallybio Corp's disclosed short interest ran from 2.23% of shares outstanding on 13 Jan 2023 to 4.80% on 15 Dec 2023, a change of +2.57 percentage points. The year's high was 5.65% on 15 Nov 2023 and its low 2.00% on 15 Jun 2023, averaging 3.03% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 53.93 days on 31 Oct 2023. Full history: Rallybio Corp.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Rallybio Corp in 2023

2023 in figures

Start of year
2.23% (13 Jan 2023)
End of year
4.80% (15 Dec 2023)
Change
+2.57 pp
High
5.65% (15 Nov 2023)
Low
2.00% (15 Jun 2023)
Average
3.03%
Highest days to cover
53.93 (31 Oct 2023)
SEC filings marked
8

Every report in 2023

Rallybio Corp short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.23%18.74
31 Jan 20232.28%10.29
15 Feb 20232.47%18.97
28 Feb 20232.48%16.04
15 Mar 20232.33%7.6410-K filed, results (8-K)
31 Mar 20232.40%15.41
14 Apr 20232.43%16.27
28 Apr 20232.46%39.27
15 May 20232.46%36.6410-Q filed, results (8-K)
31 May 20232.46%17.29
15 Jun 20232.00%7.51
30 Jun 20232.84%3.38
14 Jul 20232.98%21.91
31 Jul 20232.81%20.27
15 Aug 20232.79%31.1410-Q filed, results (8-K)
31 Aug 20232.66%38.09
15 Sep 20232.65%27.64
29 Sep 20232.68%22.96
13 Oct 20232.56%18.03
31 Oct 20235.61%53.93
15 Nov 20235.65%19.6210-Q filed, results (8-K)
30 Nov 20235.61%15.33
15 Dec 20234.80%11.04

See also: Rallybio Corp's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.